American Society of Hematology (ASH) Annual Meeting 2023
Dec 12, 2023
Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment
Date of Abstract presentation9th December 2023IndicationsChronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)Abstract Number330Abstract typeOral TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymp...
Read More...
Dec 11, 2023
Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Manageable Safety as a Second-Line Treatment for Relapsed Follicular Lymphoma
Date of Abstract presentation10th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number602Abstract typeOral In the TRANSCEND FL study, 130 individuals grappling with relapsed or refractory follicular lymphoma (FL) were actively involved and subjected to BREYANZI treatment within the second-line and thi...
Read More...
Dec 08, 2023
Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!
The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference w...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
